Neurology News

Cyclo Therapeutics announced that a phase 2b study for its investigational drug Trappsol Cyclo, which targets the reduction of amyloid beta and tau in the treatment of early Alzheimer’s disease, is now underway.

LAS VEGAS — Research has shown that racial and ethnic differences in pain management exist, and clinicians need to work to mitigate these disparities, according to a speaker at PAINWeek 2022.

In this edition, lecanemab study shows reduction in clinical decline for early AD; multimorbidity associated with increased risk for dementia, Crenezumab not effective in treating Alzheimer's disease and more.

The risk for heart disease, stroke, disability and mortality among adults with diabetes is higher for those diagnosed at age 50 to 59 years than those diagnosed at age 70 years or older, according to study findings.

SAN DIEGO – Regardless of dementia type, patients with nonamnestic symptoms showed a faster rate of functional decline than those amnestic symptoms, according to a study presented at the Alzheimer’s Association International Conference.

LAS VEGAS — Rapid reduction of symptoms and pain, achieved through the most effective drug and nondrug treatments, is a key priority for patients who experience acute migraines, according to a presenter at BRAINWeek 2022.

Treatment with sildenafil or tadalafil was not associated with a reduced risk for incident Alzheimer’s disease and related dementia in patients with pulmonary hypertension, according to a study published in Brain Communications.

LAS VEGAS — Aggressive screening, grading of injury and early initiation of antithrombotic therapy may reduce risk for stroke in patients with blunt cerebrovascular injury, according to a presenter at BRAINWeek 2022.

Alzamend Neuro has submitted an investigational new drug application to the FDA for its Alzheimer’s immunotherapeutic product, ALZN002, according to a company press release.

HHS has released two new reports that it said not only “illustrate the urgency of addressing skyrocketing prescription drug costs in America,” but also highlight the potential positive impact of the Inflation Reduction Act.